FinanceAsianet Newsable
CAPR stock nears worst month in 9 years on FDA doubts
in5points
CAPR stock is on track for its worst month in 9 years amid FDA approval doubts.
Roth, B. Riley and Cantor flagged elevated approval risk for CAPR's drug.
Martin Shkreli has increased his stake in CAPR, adding to regulatory scrutiny.
Despite the selloff, retail investor bullishness on CAPR has reached an all-time high.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically